Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of bla OXA-23 on efficacy
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Yasmeen Abouelhassan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Sulbactam, Acinetobacter Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: U.S. Food and Drug Administration, Center for Anti-Infective Research and Development, Hartford Hospital.
Abstract (Originalsprache)
Objectives
We evaluated the efficacies of human-simulated regimens (HSRs) of two clinically utilized sulbactam regimens: 1 g q6h 0.5 h infusion (maximum FDA-approved dosage) and 3 g q8h 4 h infusion (high-dose, prolonged-infusion regimen), against Acinetobacter baumannii in a translational murine model.
Methods
Thirty-two clinical A. baumannii isolates were investigated, of which 16 were sulbactam resistant (MIC ≥ 16 mg/L), 6 were sulbactam intermediate (MIC = 8 mg/L) and 10 were sulbactam susceptible (MIC ≤ 4 mg/L). Efficacies of the two sulbactam HSRs were assessed in the neutropenic murine pneumonia model. Changes in log10 cfu/lungs at 24 h compared with 0 h controls were measured, and efficacy was defined as achieving 1 log kill relative to baseline. WGS of the isolates and bioinformatics analysis were performed to explore potential associations between the genomic backgrounds and the in vivo responses.
Results
Eleven isolates harboured blaOXA-23, of which 10 were sulbactam resistant, 1 was sulbactam intermediate while none was sulbactam susceptible. Both sulbactam HSRs achieved >1 log kill against sulbactam-susceptible isolates. Against sulbactam-intermediate and sulbactam-resistant isolates, lack of efficacy correlated with the presence of the blaOXA-23 gene; sulbactam 1 g HSR and 3 g HSR did not show efficacy against 11/11 and 9/11 blaOXA-23-positive isolates, respectively, while efficacy was observed against all 11 blaOXA-23-negative sulbactam-intermediate and sulbactam-resistant isolates (i.e. harbouring other resistance genes).
Conclusions
A sulbactam high-dose prolonged-infusion regimen provides comparable activity to the standard dose against isolates currently considered sulbactam susceptible. However, the activity against isolates with intermediate and resistant susceptibility could be predicted by the detection of blaOXA-23. Enhancing detection capabilities of common diagnostic modalities to include OXA-23 can improve patient outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
- Division of Infectious Diseases, Hartford Hospital, Hartford, CT, USA.
ORCID-Profile: Yasmeen Abouelhassan, Kamilia Abdelraouf
Förderung
- U.S. Food and Drug Administration
- Center for Anti-Infective Research and Development
- Hartford Hospital
- US Food and Drug Administration
Zitieren
APA
Abouelhassan, Y., Nicolau, D. P., & Abdelraouf, K. (2024). Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of bla OXA-23 on efficacy. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae229
Vancouver
Abouelhassan Y, Nicolau DP, Abdelraouf K. Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of bla OXA-23 on efficacy. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae229
BibTeX
@article{Abouelhassan2024,
author = {Abouelhassan, Yasmeen and Nicolau, David P and Abdelraouf, Kamilia},
title = {Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of bla OXA-23 on efficacy},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae229}
}
EUVIMED